Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: The efficacy of adjunctive N-acetylcysteine in major depressive disorder : a double-blind, randomized, placebo-controlled trial
Author: Berk, M.
Dean, O.
Cotton, S.
Jeavons, S.
Tanious, M.
Kohlmann, K.
Hewitt, K.
Moss, K.
Allwang, C.
Schapkaitz, I.
Robbins, J.
Cobb, H.
Ng, F.
Dodd, S.
Bush, A.
Malhi, G.
Citation: The Journal of Clinical Psychiatry, 2014; 75(6):628-636
Publisher: Physicians Postgraduate Press
Issue Date: 2014
ISSN: 0160-6689
Statement of
Michael Berk, Olivia M. Dean, Sue M.Cotton, Susan Jeavons, Michelle Tanious, Kristy Kohlmann, Karen Hewitt, Kirsteen Moss, Christine Allwang, Ian Schapkaitz, Jenny Robbins, Heidi Cobb, Felicity Ng, Seetal Dodd, Ashley I. Bush, Gin S. Malhi
Abstract: Objective: Major depressive disorder (MDD) is one of the most common psychiatric disorders, conferring considerable individual, family, and community burden. To date, treatments for MDD have been derived from the monoamine hypothesis, and there is a paucity of emerging antidepressants, especially with novel mechanisms of action and treatment targets. N-acetylcysteine (NAC) is a redox-active glutathione precursor that decreases inflammatory cytokines, modulates glutamate, promotes neurogenesis, and decreases apoptosis, all of which contribute to the neurobiology of depression. Method: Participants with a current episode of MDD diagnosed according to DSM-IV-TR criteria (N = 252) were treated with NAC or placebo in addition to treatment as usual for 12 weeks and were followed to 16 weeks. Data were collected between 2007 and 2011. Results: The omnibus interaction between group and visit for the Montgomery-Asberg Depression Rating Scale (MADRS), the primary outcome measure, was not significant (F₁,₅₂₀.₉ = 1.98, P = .067), and the groups did not separate at week 12 (t₃₆₀.₃ = -1.12, P = .265). However, at week 12, the scores on the Longitudinal Interval Follow-Up Evaluation-Range of Impaired Functioning Tool (LIFE-RIFT) differed from placebo (P = .03). Among participants with a MADRS score >/- 25, NAC separated from placebo at weeks 6, 8, 12, and 16 (P < .05). Additionally, the rate of change between baseline and week 16 was significant (t₂₂₁.₀₃ = -2.11, P = .036). NAC treatment was superior to placebo at week 16 for secondary readouts of function and clinical impression. Remission and response were greater in the NAC group at week 16, but not at week 12. The NAC group had a greater rate of gastrointestinal and musculoskeletal adverse events. Conclusions: Being negative at the week 12 end point, and with some positive secondary signals, the study provides only limited support for the role of NAC as a novel adjunctive therapy for MDD. These data implicate the pathways influenced by NAC in depression pathogenesis, principally oxidative and inflammatory stress and glutamate, although definitive confirmation remains necessary.
Keywords: Humans; Acetylcysteine; Antidepressive Agents; Drug Therapy, Combination; Questionnaires; Follow-Up Studies; Double-Blind Method; Depressive Disorder, Major; Adult; Middle Aged; Patient Satisfaction; Female; Male
Rights: © Copyright 2014 Physicians Postgraduate Press Inc. not for distribution, display or commercial purposes
RMID: 0030028044
DOI: 10.4088/JCP.13m08454
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.